NCT04962867招募中2 期
Multicenter Investigator-initiated Phase II Trial of E7090 in Patients With Advanced or Recurrent Solid Tumor With Fibroblast Growth Factor Receptor (FGFR) Gene Alteration (FORTUNE Trial)
National Cancer Center, Japan14 个研究点 分布在 1 个国家目标入组 75 人开始时间: 2021年6月15日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 75
- 试验地点
- 14
- 主要终点
- Objective response rate (ORR)
研究概览
简要总结
This is a single-arm, open-label, multicenter, investigator-initiated Phase 2 trial to evaluate the efficacy and safety of E7090 in patients with advanced or recurrent solid tumors harboring FGFR genetic alterations (including fusion, mutation, amplification).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants with histologically or cytologically confirmed metastatic, unresectable, or recurrent solid tumor who agree to provide an archival tumor sample, a residual biopsy sample, or a fresh tumor biopsy sample
- •Ineffective to or intolerant to initial treatment, or for which standard treatment is no longer available
- •Participants with an FGFR gene alteration detected by NGS panel, who fall under one of the categories of groups A to C and E defined as below
- •Group A: FGFR1-3 fusion
- •Group B and E: FGFR1-3 specific activating mutations as below;
- •FGFR1: P150S, T340M, R445W, N546K, K656E
- •FGFR2: C62Y, A67V, N82K, D101Y, E160K, E163K, M186T, R203H, R210Q, Q212K, R251Q, S252W, P253R, P253L, A264T, W290C, K310R, Y328N, G364E, Y375C, C382R, A389T, V392A, R399Q, H416R, I422V, H544Q, N549H, N549K, N549D, N549S, L560F, K659E, K659N, R664W, E718K, S791T
- •FGFR3: G380E, G380R, A391E, K650T, K650E, K650Q, K650N
- •Group C: FGFR1-3 activating mutation not applicable to group B, or FGFR1, 2 gene amplification
- •For Group D, participants with cholangiocarcinoma who have previously received a selective FGFR inhibitor other than E7090 and have demonstrated progressive disease or resistance
- •Karnofsky Performance Status (KPS) >= 70 for patients with primary CNS tumors. Performance Status (ECOG) 0-1 for patients with non-primary CNS tumors
- •For patients with non-primary CNS tumors, they have at least 1 lesion of >= 10 millimeter (mm) in the longest diameter for a non-lymph node or >= 15 mm in the short-axis diameter for a lymph node that is considered as serially measurable according to RECIST v1.1 using computerized tomography or magnetic resonance imaging (CT or MRI) within 28 days of enrollment. However, lesions that have received local treatment such as external-beam radiation therapy (EBRT) or radiofrequency ablation (RFA) must have progressed after these local treatment to count as measurable lesion
- •Participants with primary CNS tumors must meet all of the following criteria:
- •Have received prior treatment including radiation and/or chemotherapy, as recommended or appropriate for the CNS tumor type
- •Have >= 1 site of bi-dimensionally measurable disease (confirmed by magnetic resonance imaging (MRI) and evaluable by RANO criteria), with the size of at least one of the measurable lesions >= 1 cm in each dimension and noted on more than one imaging slice. Imaging study performed within 28 days before enrollment
- •Must be neurologically stable based on neurologic exam at least for the last 7 days prior to enrollment. (based on medical examination/interview)
- •Corrected calcium <= 10.1 mg/dL
- •Phosphate <= 4.6 mg/dL
- •Required treatment washout period, from the last day of prior treatment until enrollment of this trial, is as follows:
- •Antibody and other investigational drugs: >= 28 days
- •Prior chemotherapy (excluding small-molecule targeted therapy), surgical therapy, radiation therapy: >= 21 days (>= 90 days from the date of the last radiation therapy for primary CNS tumors)
- •Endocrine therapy, immunotherapy, small-molecule targeted therapy: >=14 days
排除标准
- •Participants with brain, subdural or leptomeningeal metastases
- •Participants with primary CNS tumor located in either cerebellum, brainstem, spinal cord, pituitary gland, optic nerve or olfactory nerve
- •Positive for either human immunodeficiency virus (HIV) antibody, HBs antigen, or HCV antibody (patients with positive HCV antibody but no detectable HCV-RNA are not excluded)
- •Negative for HBs antigen, but positive for HBs antibody or HBc antibody, and also positive for HBV-DNA quantification (not excluded if HBV-DNA is below detection sensitivity)
- •Child-Pugh score B or C
- •Participants with pericardial effusion, pleural effusion, or ascites requiring treatment
- •Have any of the following ocular diseases
- •Grade 2 or higher corneal disorders
- •Active retinopathy (e.g., age-related macular degeneration, central serous chorioretinal disease, retinal tear)
- •Participants whose toxicity of previous treatment has not recovered to Grade 1 or lower per Common Terminology Criteria for Adverse Events (CTCAE v5.0), except for alopecia, infertility, and the laboratory test results listed in the inclusion criteria
- •Participants who received a prior selective FGFR inhibitor in the recurrent/metastatic disease setting; except for patients with cholangiocarcinoma harboring FGFR2 fusion (Group D). Note that prior use of a multi-kinase inhibitor which includes anti-FGFR activity is acceptable after review by the lead investigator
- •Participants who need the use of drugs that strongly inhibits or induces the metabolizing enzyme cytochrome P450 (CYP) 3A
- •The presence of FGFR gatekeeper mutations as follows: FGFR1 V561, FGFR2 V564/565, FGFR3 V555/557, FGFR4 V550
- •The presence of any of the following coexisting driver gene abnormalities:
- •Genetic mutations (excluding VUS): KRAS, NRAS, EGFR, or BRAF V600
- •Gene translocations: ALK, ROS1, or NTRK
结局指标
主要结局
Objective response rate (ORR)
时间窗: Baseline up to 3.5 years
Overall response rate (ORR) defined as the combined incidence of complete response (CR) and PR, confirmed no less than 4 weeks after the criteria for response are first met, based on RECIST v1.1. ORR will be confirmed by independent blinded central review assessment.
次要结局
- Objective response rate (ORR)(Baseline up to 3.5 years)
- Progression-free survival (PFS)(Baseline up to 3.5 years)
- Disease control rate (DCR)(Baseline up to 3.5 years)
- Overall Survival (OS)(Baseline up to 3.5 years)
- Adverse reaction (adverse drug reaction) rate(From the first dose of the investigational product until 30 days after the last dose of study drugs)
- Duration of response (DOR)(Baseline up to 3.5 years)
- Adverse event (AE) rate(From the first dose of the investigational product until 30 days after the last dose of study drugs)
- Time to response (TTR)(Baseline up to 3.5 years)
研究者
研究点 (14)
Loading locations...
相似试验
Unknown
2 期
Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast CancerHER2-negative Breast CancerNCT04624711The First Affiliated Hospital with Nanjing Medical University40
招募中
2 期
A Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Cervical CancerCervical CancerNCT05557565Qilu Pharmaceutical Co., Ltd.150
已完成
2 期
First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBCTriple Negative Breast CancerMetastatic Breast CancerAdvanced Breast CancerNCT04408118MedSIR100
进行中（未招募）
2 期
TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung CancerNCT05955391Shenzhen TargetRx, Inc.164
招募中
2 期
A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard TherapyMSI-H Solid Malignant TumorNCT03941574Shanghai Henlius Biotech108